WO2008051526A3 - Bone morphogenetic proteins - Google Patents

Bone morphogenetic proteins Download PDF

Info

Publication number
WO2008051526A3
WO2008051526A3 PCT/US2007/022454 US2007022454W WO2008051526A3 WO 2008051526 A3 WO2008051526 A3 WO 2008051526A3 US 2007022454 W US2007022454 W US 2007022454W WO 2008051526 A3 WO2008051526 A3 WO 2008051526A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone morphogenetic
type
binding site
morphogenetic proteins
receptor binding
Prior art date
Application number
PCT/US2007/022454
Other languages
French (fr)
Other versions
WO2008051526A9 (en
WO2008051526A2 (en
Inventor
Moulay Hicham Alaoui-Ismaili
Jimin Wang
Kening Song
Robert K Suto
Original Assignee
Stryker Corp
Moulay Hicham Alaoui-Ismaili
Jimin Wang
Kening Song
Robert K Suto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp, Moulay Hicham Alaoui-Ismaili, Jimin Wang, Kening Song, Robert K Suto filed Critical Stryker Corp
Publication of WO2008051526A2 publication Critical patent/WO2008051526A2/en
Publication of WO2008051526A9 publication Critical patent/WO2008051526A9/en
Publication of WO2008051526A3 publication Critical patent/WO2008051526A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Abstract

The present invention provides modified highly potent bone morphogenetic proteins. In particular, the present invention features a chimeric bone morphogenetic protein including a dimer with each monomer containing a type I receptor binding site derived from a member of the BMP subfamily and a type II receptor binding site derived from a member of the TGF-β subfamily. As a result, the chimeric bone morphogenetic protein has improved binding affinity to type II receptor relative to the naturally-occurring BMP subfamily member from which the type I receptor binding site is derived. Also provided are modified bone morphogenetic proteins having reduced affinity for Noggin. Other embodiments of modified BMPs, compositions and method of use are also included.
PCT/US2007/022454 2006-10-23 2007-10-23 Bone morphogenetic proteins WO2008051526A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85403906P 2006-10-23 2006-10-23
US60/854,039 2006-10-23

Publications (3)

Publication Number Publication Date
WO2008051526A2 WO2008051526A2 (en) 2008-05-02
WO2008051526A9 WO2008051526A9 (en) 2008-06-19
WO2008051526A3 true WO2008051526A3 (en) 2009-03-12

Family

ID=39325157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022454 WO2008051526A2 (en) 2006-10-23 2007-10-23 Bone morphogenetic proteins

Country Status (1)

Country Link
WO (1) WO2008051526A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
AU2010341565A1 (en) * 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN103079585B (en) 2010-08-20 2015-09-30 惠氏有限责任公司 Through the BMP of design
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
AU2015202418B2 (en) * 2010-08-20 2017-02-02 Wyeth Llc Designer osteogenic proteins
WO2020101366A1 (en) * 2018-11-15 2020-05-22 joint Center for Biosciences Activin/bmp7 chimeras: super-active sab704 and sab715, and their respective noggin-sensitized variants, nab704 and nab715; and nab204

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
WO2000020449A2 (en) * 1998-10-07 2000-04-13 Stryker Corporation MODIFIED TGF-β SUPERFAMILY PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
WO2000020449A2 (en) * 1998-10-07 2000-04-13 Stryker Corporation MODIFIED TGF-β SUPERFAMILY PROTEINS

Also Published As

Publication number Publication date
WO2008051526A9 (en) 2008-06-19
WO2008051526A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008051526A3 (en) Bone morphogenetic proteins
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2006119062A3 (en) Sclerostin epitopes
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2007127317A3 (en) Humanized c-kit antibody
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
WO2007098420A3 (en) Peptides that block the binding of igg to fcrn
EP3320913A3 (en) Designer osteogenic proteins
WO2008079246A3 (en) Cd44 antibodies
WO2009120995A3 (en) Collagen-binding synthetic peptidoglycans, preparation, and methods of use
WO2004082608A3 (en) Ligands for tgf-beta binding proteins and uses thereof
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2007120638A3 (en) Methods and compositions for modulating glycosylation
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
EP1829840A3 (en) A binder composition, a construction comprising said binder composition, as well as a method for preparing the construction composition and use thereof.
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2004013160A3 (en) Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
ATE543833T1 (en) BMP-7 VARIANT COMPOSITIONS, METHODS AND USES
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2008061108A3 (en) Phthalazine derivatives
WO2008021375A3 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867265

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867265

Country of ref document: EP

Kind code of ref document: A2